ADC Therapeutics reports Q1 2026 results, $20M revenue, and expects LOTIS-5 Phase 3 data in Q2 2026

ADC Therapeutics announced $20 million in net product revenue for Q1 2026 and reported a net loss of $33 million, improving from the previous year. The company expects topline Phase 3 data from its LOTIS-5 trial in Q2 2026, with full data from LOTIS-5 and LOTIS-7 anticipated by year-end. Positive results could lead to FDA supplemental approval submissions and expanded use of their cancer drug ZYNLONTA. ADC maintains a strong cash position of $231 million, supporting operations into 2028.